Escasas y probables complicaciones neurológicas de las vacunas contra el Sars-Cov-2

Erik Guevara-Silva; Sheila Castro-Suarez

doi:10.20453/rnp.v84i3.4031

Erik Guevara-Silva Centro de Investigación Básica en Demencia y Enfermedades desmielinizantes del Sistema Nervioso, Instituto Nacional de Ciencias Neurológicas. Lima, Perú.
Sheila Castro-Suarez Centro de Investigación Básica en Demencia y Enfermedades desmielinizantes del Sistema Nervioso, Instituto Nacional de Ciencias Neurológicas. Lima, Perú. Atlantic Senior Fellow of Global Brain Health Institute.San Francisco, USA.

DOI: https://doi.org/10.20453/rnp.v84i3.4031

Referencias

Karnik M, Beeraka NM, Uthaiah CA, Nataraj SM, Bettadapura ADS, Aliev G, et al. A Review on SARS-CoV-2-Induced Neuroinflammation, Neurodevelopmental Complications, and Recent Updates on the Vaccine Development. Mol Neurobiol. 2021;1-29. doi: 10.1007/s12035-021-02399-6

World Health Organization. WHO Coronavirus (COVID-19) Dashboard. Ginebra: World Health Organization. (Citado el 18 de setiembre del 2021) Disponible en: .https://covid19.who.int/

Wu F, Zhao S, Yu B, Chen Y-M, Wang W, Song Z-G, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579 (7798):265–9. Doi: 10.1038/s41586-020-2008-3

Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–8. Doi: 10.1038/s41591-020-1124-9

Le TT, Cramer JP, Chen R, Mayhew S. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19(10):667–668. Doi: 10.1038/d41573-020-00151-8

Goss AL, Samudralwar RD, Das RR, Nath A. ANA Investigates: Neurological Complications of COVID-19 Vaccines. Ann Neurol. 2021;89(5):856– 86

Doi: 10.1002/ana.260657. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–27. Doi: 10.1038/ s41586-020-2798-3

U.S. Food and Drug Administration. COVID-19 Vaccines. Washington DC: U.S. Food and Drug Administration; 2021. (Citado el 18 de setiembre del 2021) Disponible en: h t t p s : / / w w w . f d a . g o v / emergency-preparedness-and-response/coronavirus- disease-2019-covid-19/covid-19-vaccines

Organización Mundial de la Salud. Vacunas con la COVID-19. Ginebra: Organización Mundial de la Salud; 2021.(Citado el 18 de setiembre del 2021) Disponible en: https://www.who.int/es/emergencies/ diseases/novel-coronavirus-2019/covid-19-vaccines

U.S. Food and Drug Administration. La FDA aprueba la primera vacuna contra el COVID-19. Washington DC: U.S. Food and Drug Administration; 2021. (Citado el 18 de setiembre del 2021) Disponible en: https://www.fda.gov/news-events/press- announcements/la-fda-aprueba-la-primera-vacuna-contra-el-covid-19

World Health Organization. WHO Director-General’s opening remarks at the Special Ministerial Meeting: A Vaccine for All. Ginebra: World Health Organization. (Citado el 18 de setiembre del 2021) Disponible en: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-special-ministerial-meeting-a-vaccine-for-all

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/ NEJMoa2034577

Waheed S, Bayas A, Hindi F, Rizvi Z, Espinosa PS. Neurological Complications of COVID-19: Guillain- Barre Syndrome Following Pfizer COVID-19 Vaccine. Cureus. 2021;13(2):e13426. Doi: 10.7759/ cureus.13426

Volpicelli G. They Claimed the Covid Vaccine Made Them Sick—and Went Viral. WIRED; 2021. (Citado el 18 de setiembre del 2021) Disponible en: https:// www.wired.com/story/they-claimed-the-covid- vaccine-made-them-sick-and-went-viral/